Axcan Holdings Inc. has reached an agreement to acquire Dutch pharmaceutical company Eurand N.V. in a cash deal worth roughly $583 million, the companies announced Wednesday.

Axcan, which has corporate offices in Quebec and specializes in pharmaceuticals that treat gastrointestinal disorders, will pay $12.00 per share for Eurand. The agreement calls for a wholly owned subsidiary of Axcan to put forth a tender offer to Eurand’s shareholders for all outstanding shares. An independent special committee of Eurand’s board of directors also was involved in the negotiations and approved the acquisition, which is expected to close in the second quarter of 2011.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]